2023-06-012024-05-312024-05-31false10166034CLINICURVE LTD2024-11-05iso4217:GBPxbrli:pure101660342023-06-01101660342024-05-31101660342023-06-012024-05-31101660342022-06-01101660342023-05-31101660342022-06-012023-05-3110166034bus:SmallEntities2023-06-012024-05-3110166034bus:AuditExempt-NoAccountantsReport2023-06-012024-05-3110166034bus:FullAccounts2023-06-012024-05-3110166034bus:PrivateLimitedCompanyLtd2023-06-012024-05-3110166034core:WithinOneYear2024-05-3110166034core:AfterOneYear2024-05-3110166034core:WithinOneYear2023-05-3110166034core:AfterOneYear2023-05-3110166034core:ShareCapital2024-05-3110166034core:SharePremium2024-05-3110166034core:RevaluationReserve2024-05-3110166034core:OtherReservesSubtotal2024-05-3110166034core:RetainedEarningsAccumulatedLosses2024-05-3110166034core:ShareCapital2023-05-3110166034core:SharePremium2023-05-3110166034core:RevaluationReserve2023-05-3110166034core:OtherReservesSubtotal2023-05-3110166034core:RetainedEarningsAccumulatedLosses2023-05-3110166034core:LandBuildings2024-05-3110166034core:PlantMachinery2024-05-3110166034core:Vehicles2024-05-3110166034core:FurnitureFittings2024-05-3110166034core:OfficeEquipment2024-05-3110166034core:NetGoodwill2024-05-3110166034core:IntangibleAssetsOtherThanGoodwill2024-05-3110166034core:ListedExchangeTraded2024-05-3110166034core:UnlistedNon-exchangeTraded2024-05-3110166034core:LandBuildings2023-05-3110166034core:PlantMachinery2023-05-3110166034core:Vehicles2023-05-3110166034core:FurnitureFittings2023-05-3110166034core:OfficeEquipment2023-05-3110166034core:NetGoodwill2023-05-3110166034core:IntangibleAssetsOtherThanGoodwill2023-05-3110166034core:ListedExchangeTraded2023-05-3110166034core:UnlistedNon-exchangeTraded2023-05-3110166034core:LandBuildings2023-06-012024-05-3110166034core:PlantMachinery2023-06-012024-05-3110166034core:Vehicles2023-06-012024-05-3110166034core:FurnitureFittings2023-06-012024-05-3110166034core:OfficeEquipment2023-06-012024-05-3110166034core:NetGoodwill2023-06-012024-05-3110166034core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3110166034core:ListedExchangeTraded2023-06-012024-05-3110166034core:UnlistedNon-exchangeTraded2023-06-012024-05-3110166034core:MoreThanFiveYears2023-06-012024-05-3110166034core:Non-currentFinancialInstruments2024-05-3110166034core:Non-currentFinancialInstruments2023-05-3110166034dpl:CostSales2023-06-012024-05-3110166034dpl:DistributionCosts2023-06-012024-05-3110166034core:LandBuildings2023-06-012024-05-3110166034core:PlantMachinery2023-06-012024-05-3110166034core:Vehicles2023-06-012024-05-3110166034core:FurnitureFittings2023-06-012024-05-3110166034core:OfficeEquipment2023-06-012024-05-3110166034dpl:AdministrativeExpenses2023-06-012024-05-3110166034core:NetGoodwill2023-06-012024-05-3110166034core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3110166034dpl:GroupUndertakings2023-06-012024-05-3110166034dpl:ParticipatingInterests2023-06-012024-05-3110166034dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-012024-05-3110166034core:ListedExchangeTraded2023-06-012024-05-3110166034dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-012024-05-3110166034core:UnlistedNon-exchangeTraded2023-06-012024-05-3110166034dpl:CostSales2022-06-012023-05-3110166034dpl:DistributionCosts2022-06-012023-05-3110166034core:LandBuildings2022-06-012023-05-3110166034core:PlantMachinery2022-06-012023-05-3110166034core:Vehicles2022-06-012023-05-3110166034core:FurnitureFittings2022-06-012023-05-3110166034core:OfficeEquipment2022-06-012023-05-3110166034dpl:AdministrativeExpenses2022-06-012023-05-3110166034core:NetGoodwill2022-06-012023-05-3110166034core:IntangibleAssetsOtherThanGoodwill2022-06-012023-05-3110166034dpl:GroupUndertakings2022-06-012023-05-3110166034dpl:ParticipatingInterests2022-06-012023-05-3110166034dpl:GroupUndertakingscore:ListedExchangeTraded2022-06-012023-05-3110166034core:ListedExchangeTraded2022-06-012023-05-3110166034dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-06-012023-05-3110166034core:UnlistedNon-exchangeTraded2022-06-012023-05-3110166034core:NetGoodwill2024-05-3110166034core:IntangibleAssetsOtherThanGoodwill2024-05-3110166034core:LandBuildings2024-05-3110166034core:PlantMachinery2024-05-3110166034core:Vehicles2024-05-3110166034core:FurnitureFittings2024-05-3110166034core:OfficeEquipment2024-05-3110166034core:AfterOneYear2024-05-3110166034core:WithinOneYear2024-05-3110166034core:ListedExchangeTraded2024-05-3110166034core:UnlistedNon-exchangeTraded2024-05-3110166034core:ShareCapital2024-05-3110166034core:SharePremium2024-05-3110166034core:RevaluationReserve2024-05-3110166034core:OtherReservesSubtotal2024-05-3110166034core:RetainedEarningsAccumulatedLosses2024-05-3110166034core:NetGoodwill2023-05-3110166034core:IntangibleAssetsOtherThanGoodwill2023-05-3110166034core:LandBuildings2023-05-3110166034core:PlantMachinery2023-05-3110166034core:Vehicles2023-05-3110166034core:FurnitureFittings2023-05-3110166034core:OfficeEquipment2023-05-3110166034core:AfterOneYear2023-05-3110166034core:WithinOneYear2023-05-3110166034core:ListedExchangeTraded2023-05-3110166034core:UnlistedNon-exchangeTraded2023-05-3110166034core:ShareCapital2023-05-3110166034core:SharePremium2023-05-3110166034core:RevaluationReserve2023-05-3110166034core:OtherReservesSubtotal2023-05-3110166034core:RetainedEarningsAccumulatedLosses2023-05-3110166034core:NetGoodwill2022-06-0110166034core:IntangibleAssetsOtherThanGoodwill2022-06-0110166034core:LandBuildings2022-06-0110166034core:PlantMachinery2022-06-0110166034core:Vehicles2022-06-0110166034core:FurnitureFittings2022-06-0110166034core:OfficeEquipment2022-06-0110166034core:AfterOneYear2022-06-0110166034core:WithinOneYear2022-06-0110166034core:ListedExchangeTraded2022-06-0110166034core:UnlistedNon-exchangeTraded2022-06-0110166034core:ShareCapital2022-06-0110166034core:SharePremium2022-06-0110166034core:RevaluationReserve2022-06-0110166034core:OtherReservesSubtotal2022-06-0110166034core:RetainedEarningsAccumulatedLosses2022-06-0110166034core:AfterOneYear2023-06-012024-05-3110166034core:WithinOneYear2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:CostValuation2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3110166034core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3110166034core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3110166034core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3110166034core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3110166034core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3110166034core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3110166034core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3110166034core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3110166034core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3110166034core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3110166034core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3110166034core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3110166034core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3110166034core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3110166034core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3110166034core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3110166034core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3110166034core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3110166034bus:Director12023-06-012024-05-31

CLINICURVE LTD

Registered Number
10166034
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2024

CLINICURVE LTD
Company Information
for the year from 1 June 2023 to 31 May 2024

Director

NOBLE-THOMPSON, Richard

Registered Address

Barge Crook 26 The Moorings
Quay Road
Barking
IG11 7FW

Registered Number

10166034 (England and Wales)
CLINICURVE LTD
Statement of Financial Position
31 May 2024

Notes

2024

2023

£

£

£

£

Current assets
Debtors3376376
Cash at bank and on hand30,90629,763
31,28230,139
Creditors amounts falling due within one year4(31,281)(30,138)
Net current assets (liabilities)11
Total assets less current liabilities11
Net assets11
Capital and reserves
Called up share capital11
Shareholders' funds11
The financial statements were approved and authorised for issue by the Director on 5 November 2024, and are signed on its behalf by:
NOBLE-THOMPSON, Richard
Director
Registered Company No. 10166034
CLINICURVE LTD
Notes to the Financial Statements
for the year ended 31 May 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at transaction price and measured at amortised cost using the effective interest method. Where investments in non-derivative financial instruments are publicly traded, or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value through profit and loss. All other investments are subsequently measured at cost less impairment. Financial assets which are measured at cost or amortised cost are reviewed for objective evidence of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. All equity instruments, regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment.
2.Average number of employees

20242023
Average number of employees during the year11
3.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables11
Prepayments and accrued income375375
Total376376
4.Creditors: amounts due within one year

2024

2023

££
Amounts owed to related parties9,46514,138
Taxation and social security21,81616,000
Total31,28130,138
5.Controlling party
The ultimate controlling party is Mr Richard Noble-Thompson.